Latest Insider Transactions at Biogen Inc. (BIIB)
This section provides a real-time view of insider transactions for Biogen Inc. (BIIB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOGEN INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOGEN INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2023
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
568
-16.66%
|
$153,360
$270.06 P/Share
|
|
Mar 02
2023
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
687
-9.17%
|
$184,116
$268.75 P/Share
|
|
Mar 02
2023
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
297
+7.71%
|
-
|
|
Feb 17
2023
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
233
-4.37%
|
$64,774
$278.38 P/Share
|
|
Feb 17
2023
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
480
+7.92%
|
-
|
|
Feb 17
2023
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
151
-3.82%
|
$41,978
$278.38 P/Share
|
|
Feb 17
2023
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
460
+10.43%
|
-
|
|
Feb 17
2023
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
238
-6.67%
|
$66,164
$278.38 P/Share
|
|
Feb 17
2023
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
512
+11.76%
|
-
|
|
Feb 17
2023
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,310
-14.73%
|
$364,180
$278.38 P/Share
|
|
Feb 17
2023
|
Michael R Mcdonnell EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,561
+20.15%
|
-
|
|
Feb 17
2023
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
371
-6.76%
|
$103,138
$278.38 P/Share
|
|
Feb 17
2023
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
767
+11.53%
|
-
|
|
Feb 17
2023
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
929
-1.98%
|
$258,262
$278.38 P/Share
|
|
Feb 17
2023
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,920
+3.94%
|
-
|
|
Feb 17
2023
|
Ginger Gregory EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
867
-8.54%
|
$241,026
$278.38 P/Share
|
|
Feb 17
2023
|
Ginger Gregory EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
1,792
+13.93%
|
-
|
|
Feb 10
2023
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,202
-2.93%
|
$1,201,772
$286.3 P/Share
|
|
Feb 10
2023
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,023
+4.02%
|
-
|
|
Feb 10
2023
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,324
-7.07%
|
$378,664
$286.3 P/Share
|
|
Feb 10
2023
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
1,968
+12.95%
|
-
|
|
Feb 10
2023
|
Ginger Gregory EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
3,306
-8.92%
|
$945,516
$286.3 P/Share
|
|
Feb 10
2023
|
Ginger Gregory EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
3,290
+11.51%
|
-
|
|
Feb 10
2023
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
590
-5.07%
|
$168,740
$286.3 P/Share
|
|
Feb 10
2023
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,061
+11.51%
|
-
|
|
Feb 10
2023
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,105
-11.05%
|
$316,030
$286.3 P/Share
|
|
Feb 10
2023
|
Michael R Mcdonnell EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,256
+24.56%
|
-
|
|
Feb 10
2023
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
372
-9.63%
|
$106,392
$286.3 P/Share
|
|
Feb 10
2023
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,211
+23.87%
|
-
|
|
Feb 10
2023
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
1,387
-7.55%
|
$396,682
$286.3 P/Share
|
|
Feb 10
2023
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
2,611
+15.79%
|
-
|
|
Jan 25
2023
|
Priya Singhal Head of Development |
BUY
Grant, award, or other acquisition
|
Direct |
1,123
+29.75%
|
-
|
|
Jan 25
2023
|
Robin Kramer Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
887
+22.26%
|
-
|
|
Jan 25
2023
|
Rachid Izzar Head of Global Product Strat. |
BUY
Grant, award, or other acquisition
|
Direct |
1,783
+26.91%
|
-
|
|
Jan 25
2023
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+24.6%
|
-
|
|
Jan 25
2023
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,703
+11.23%
|
-
|
|
Jan 25
2023
|
Ginger Gregory EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
4,452
+30.46%
|
-
|
|
Dec 08
2022
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
156
-6.59%
|
$45,084
$289.1 P/Share
|
|
Dec 08
2022
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
350
+12.88%
|
-
|
|
Dec 02
2022
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
39
-1.39%
|
$11,622
$298.9 P/Share
|
|
Dec 02
2022
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
131
+4.46%
|
-
|
|
Dec 02
2022
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
759
-11.3%
|
$226,182
$298.9 P/Share
|
|
Dec 02
2022
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
1,710
+19.51%
|
-
|
|
Nov 14
2022
|
Ginger Gregory EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
5,610
-49.55%
|
$1,683,000
$300.11 P/Share
|
|
Oct 27
2022
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,532
-12.31%
|
$1,548,960
$280.7 P/Share
|
|
Sep 01
2022
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,428
-16.42%
|
$483,172
$199.79 P/Share
|
|
Sep 01
2022
|
Michael R Mcdonnell EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,746
+24.16%
|
-
|
|
Aug 01
2022
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
319
-5.91%
|
$66,671
$209.26 P/Share
|
|
Aug 01
2022
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
1,080
+16.28%
|
-
|
|
Jul 01
2022
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
74
-3.54%
|
$15,540
$210.63 P/Share
|